Computational biology meets oncology: designing custom protein and peptide binders to outsmart cancer

Cancer remains one of the most formidable global health challenges, with conventional therapies often limited by off-target toxicity, drug resistance, and the inability to target key oncogenic drivers. In recent years, de novo protein and peptide binder engineering has emerged as an approach to overcome these barriers, offering precise and customizable solutions for cancer diagnosis and treatment. By leveraging computational design, directed evolution, and artificial intelligence, researchers can now engineer binding molecules with high specificity, stability, and therapeutic potential, unconstrained by the limitations of natural protein scaffolds. This review explores methodologies in de novo binder design, from computational algorithms like Rosetta and AlphaFold (although, with limitations such as their accuracy for disordered regions and conformational dynamics) to innovative scaffold optimization strategies. It highlights groundbreaking applications, including direct tumor inhibition, targeted drug delivery, immune modulation, and diagnostic biosensing, while showcasing case studies such as Designed Ankyrin Repeat Proteins (DARPins) and PD-1/PD-L1 mini-protein inhibitors. Looking ahead, the field promises to improve personalized medicine through tumor-specific binders, synthetic biology circuits, and next-generation delivery systems. As a convergence of biotechnology, computational modeling, and translational medicine, de novo binder engineering represents a powerful frontier in cancer therapy, with the potential to redefine precision oncology and address unmet clinical needs. The insights presented herein underscore its growing relevance in shaping future therapeutic strategies against cancer's complexity.